血必净对急性冠脉综合征患者血清可溶性CD40配体和脂蛋白相关性磷脂酶A2的影响

Effect ofXuebijinginjection on the serum soluble CD40 ligand and lipoprotein associated phospholipase A2 of patients with acute coronary syndrome

目的：探讨血必净注射液对急性冠脉综合征（acute coronary syndrome, ACS）患者血清可溶性CD40配体（soluble CD40 ligand, sCD40L）、脂蛋白相关性磷脂酶A2（lipoprotein-phospholipase A2, Lp-PLA2）的影响。方法将符合入选标准的120例ACS患者按随机数字表法分为2组各60例，对照组采用西医常规疗法治疗，研究组在对照组基础上辅助血必净治疗，均连续治疗2周。采用ELISA法检测血清sCD40L、Lp-PLA及IL-6、TNF-α和CRP炎性细胞因子水平，评价临床疗效。结果治疗后，研究组血清sCD40L[（320.62±35.81）pg/L比（401.70±48.40）pg/L，t＝10.435]、Lp-PLA2[（203.62±33.13）μg/L比（296.45±44.22）μg/L，t＝12.831]水平，以及血清CRP[（3.10±2.00）mg/L比（4.74±2.04）mg/L，t＝4.006]、IL-6[（2.10±1.20）pg/L 比（3.14±1.40）pg/L，t＝3.781]、TNF-α[（2.81±1.50）pg/L 比（3.70±1.70）pg/L，t＝3.075]水平均明显低于对照组（P＜0.01或 P＜0.05）。研究组显效率为68.3%（41/60），对照组为50.0%（30/60），2组比较差异有统计学意义（χ2＝4.174，P＝0.041）。结论血必净注射液辅助西医常规疗法可显著降低ACS患者血清sCD40L、Lp-PLA2水平，提高临床疗效。

Objective To detect the effect ofXuebijing injection on the serum soluble CD40 ligand （soluble CD40 ligand, sCD40L）, lipoprotein associated phospholipase A2 （lipoprotein-phospholipase A2, Lp-PLA2） of patients with acute coronary syndrome （ACS）.Methods A total of 120 patients with ACS were randomized divided into the control group and treatment group, 60 in each group.The control group received the routine treatment of Western medicine, and the treatment group receivedXuebijing injectionbased on the intervention of control group. Both groups were treated for 2 weeks. ELISA method was used to detect serum sCD40L, Lp-PLA and IL-6, TNF-α and CRP.Results After treatment, the serum sCD40L（320.62 ± 35.81 pg/Lvs. 401.70 ± 4.84 pg/L, t=10.435）, Lp-PLA2 （203.62 ± 33.13μg/L vs. 296.45 ± 4.422μg/L,t=12.831） level was significantly lower than those in the control group （P〈0.01）; The serum CRP （3.10 ± 2.00 mg/Lvs.4.74 ± 2.04 mg/L,t=4.006）, IL-6 （2.10 ± 1.20 pg/Lvs.3.14 ± 1.40 pg/L,t=3.781）, TNF （2.81 ± 1.50 pg/Lvs. 3.70 ± 1.70 pg/L,t=3.075） level was significantly lower than thosein the control group （P〈0.01 orP〈0.05）. Compared with the control group, the effect rate （68.3%vs. 50.0%,χ2=4.174） of the treatment group was significantly higher （P=0.041）.ConclusionXuebijing injection can improve the therapeutic effectof ACS patients, and reduce CD40L, Lp-PLA2 levels.